Zhiyi Biotech Announced First Subject Dosed in the U.S. Phase 1 clinical Trial of SK10, in Development for Treatment of Chemotherapy-induced Diarrhea
- Written by PR Newswire
GUANGZHOU, China, Aug. 25, 2023 /PRNewswire/ -- On August 23rd 2023, Zhiyi Biotech announced that the first three subjects have been dosed in the U.S. Phase 1 clinical trial of SK10, an innovative heat-killed Bacteroides fragilis product developed by Zhiyi Biotech for Chemotherapy-induced Diarrhea (CID). The U.S. Phase 1 trial is a...
